Forty Seven Inc (NASDAQ:FTSV) Receives $25.88 Average Price Target from Analysts

Share on StockTwits

Forty Seven Inc (NASDAQ:FTSV) has been assigned a consensus rating of “Buy” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $25.88.

FTSV has been the subject of a number of research reports. Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the company a “buy” rating in a research note on Tuesday, March 19th. HC Wainwright set a $25.00 price objective on Onconova Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 14th. Guggenheim cut Anadarko Petroleum from a “buy” rating to a “hold” rating and set a $69.00 price objective for the company. in a research note on Friday, April 12th. Roth Capital initiated coverage on Forty Seven in a research note on Wednesday, May 29th. They issued a “buy” rating and a $28.00 price objective for the company. Finally, Zacks Investment Research cut Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th.

FTSV stock opened at $10.28 on Tuesday. The stock’s fifty day simple moving average is $10.98. Forty Seven has a 52-week low of $9.76 and a 52-week high of $23.83.

Forty Seven (NASDAQ:FTSV) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.14). Equities analysts expect that Forty Seven will post -2.72 EPS for the current year.

In related news, insider Mark Anthony Mccamish sold 8,199 shares of Forty Seven stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $11.02, for a total value of $90,352.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Irving Weissman sold 20,000 shares of Forty Seven stock in a transaction on Friday, April 26th. The shares were sold at an average price of $18.35, for a total value of $367,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 106,811 shares of company stock valued at $1,718,108. 37.40% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in Forty Seven by 89.5% in the fourth quarter. BlackRock Inc. now owns 845,954 shares of the company’s stock valued at $13,298,000 after purchasing an additional 399,591 shares during the period. Candriam Luxembourg S.C.A. boosted its holdings in Forty Seven by 500.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 120,000 shares of the company’s stock valued at $1,939,000 after purchasing an additional 100,000 shares during the period. Northern Trust Corp boosted its holdings in Forty Seven by 388.3% in the fourth quarter. Northern Trust Corp now owns 88,769 shares of the company’s stock valued at $1,396,000 after purchasing an additional 70,591 shares during the period. Geode Capital Management LLC boosted its holdings in Forty Seven by 103.0% in the fourth quarter. Geode Capital Management LLC now owns 88,165 shares of the company’s stock valued at $1,385,000 after purchasing an additional 44,735 shares during the period. Finally, Exane Asset Management boosted its holdings in Forty Seven by 148.1% in the first quarter. Exane Asset Management now owns 67,000 shares of the company’s stock valued at $1,083,000 after purchasing an additional 40,000 shares during the period. Hedge funds and other institutional investors own 47.34% of the company’s stock.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Read More: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.